Revenue
No reported data
Raphael Pharmaceutical Inc. (RAPH)
Price—Loading quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2022
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Research & development | $631,000 | $776,000 | $569,000 | $1.2M | $776,000 | $461,000 |
| Operating income | −$1.2M | −$1.5M | −$1.3M | −$3.3M | −$1.6M | −$706,000 |
| Net income | −$1.3M | −$1.5M | −$1.3M | −$3.4M | −$1.6M | −$718,000 |
| Basic EPSper diluted share | $0.07 | $0.08 | $0.08 | $0.23 | $0.15 | $0.07 |
| Diluted EPSper diluted share | $0.07 | $0.08 | $0.08 | $0.23 | $0.15 | $0.07 |